Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Herc who wrote (3599)	8/16/1999 9:22:00 AM
From: BMcV	Respond to of 10280

>>Seldane is an excellent example of what I'm trying to get across. There are literally hundreds of decongestents on the market, and many are OTC.<< Seldane is not a decongestant and it is not on the market. >>Most people are not overly troubled by the sedative effect of antihistamines so will opt for lower price.<< Maybe you can explain why Claritin is by far the largest and fastest growing drug in this category, then? >>So I wouldn't bet the farm on a new decongestent.<< As John Metcalf pointed out, Allegra has sales of $500 million, which seems like a pretty good bet to make. >>OK, if it's successful, than SEPR may be worth twice Merck.<< Nobody ever made this claim.

To: Herc who wrote (3599)	8/16/1999 9:32:00 AM
From: Thomas M.	Respond to of 10280

Most people are not overly troubled by the sedative effect of antihistamines so will opt for lower price. Obviously, the huge sales of non-sedative antihistamines conflict with your assertion. From your post, I gather you are not aware that a decongestant and an antihistamine are two different classes of drugs. Is this sort of in-depth knowledge is too much to ask of an opthalmologist? <g> Tom